Last reviewed · How we verify

NCT06761521: IMP_TRE

Monitoring of Implant Diseases: Diagnosis and Monitoring With aMMP-8 Test Technology

ENROLLING BY INVITATION NA Last updated 6 March 2025
What this trial tests

NA trial testing Peri-Implantitis and Peri-implant mucositis in Peri-Implant Health in 50 participants. Enrolling by invitation.

Timeline
11 January 2025
Primary endpoint
11 September 2025
20 November 2025

Quick facts

Lead sponsorHanna Lahteenmaki
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment50
Start date11 January 2025
Primary completion11 September 2025
Estimated completion20 November 2025
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Hanna Lahteenmaki

Who can join

Eligibility, any sex, with Peri-Implant Health or Peri-Implantitis and Peri-implant Mucositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

68 patients underwent the aMMP-8 chair-side test as well as clinical traditional measurement methods. Those who had one or more implants in their mouth were selected as patients. The condition of the attachment tissues of these implants is monitored at a control visit after five years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peri-Implant Health

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing